drugset / Trial / NCT00790075

Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children

NCT00790075

Phase 4 Completed 24 enrolled Stony Brook University
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to demonstrate safety and efficacy of liquid risperidone in psychiatrically hospitalized children, ages 4-12, who would be put in seclusion or restraint, or given an intramuscular injection of diphenhydramine because of their out-of-control behavior if not medicated with risperidone. The first part of the study will: 1) develop appropriate oral doses of medication to reduce out of control or agitated behavior effectively with the fewest side effects, and 2) develop a rating system to measure the children's behavior i.e. level of improvement, sedation, and untoward effects.

Timeline

Start
2003-01
Primary completion
2004-06
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 0.015 mg/kg Oral
Subject Risperidone Other / unclassified 0.02 mg/kg Oral
Subject Risperidone Other / unclassified 0.025 mg/kg Oral
Subject Risperidone Other / unclassified 0.3 mg/kg Oral

Indications

No indication recorded.